The development and characterization of a long acting anti‐thrombotic von Willebrand factor (VWF) aptamer

J. Evan Sadler III MD PhD (9 November 1951 - 13 December 2018)

(2019)   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Clinical pharmacology of caplacizumab for the treatment of patients with acquired thrombotic thrombocytopenic purpura

(2019) Maria Laura Sargentini-Maier et al.   Expert Review of Clinical Pharmacology

Platelet-rich emboli are associated with von Willebrand factor levels and have poorer revascularization outcomes

(2019) Andrew Douglas et al.   Journal of NeuroInterventional Surgery

Efficacy and safety of open‐label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study

(2019) Paul Knoebl et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

A comparative analysis of different automated von Willebrand factor glycoprotein Ib-binding activity assays in well typed von Willebrand disease patients

(2018) I. Vangenechten et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Targeting von Willebrand Factor in Ischaemic Stroke: Focus on Clinical Evidence

(2018) Nina Buchtele et al.   THROMBOSIS AND HAEMOSTASIS

Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura

(2017) F. Peyvandi et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Thrombotic thrombocytopenic purpura

(2017) Johanna A. Kremer Hovinga et al.   Nature Reviews Disease Primers

Cause-specific mortality for 240 causes in China during 1990–2013: a systematic subnational analysis for the Global Burden of Disease Study 2013

(2016) Maigeng Zhou et al.   LANCET

Increased von Willebrand factor, P-selectin and fibrin content in occlusive thrombus resistant to lytic therapy

(2016) Bruno Del Blanco et al.   THROMBOSIS AND HAEMOSTASIS

The VWF-GPIb axis in ischaemic stroke: lessons from animal models

(2016) Frederik Denorme et al.   THROMBOSIS AND HAEMOSTASIS

Platelet-derived VWF is not essential for normal thrombosis and hemostasis but fosters ischemic stroke injury in mice

(2015) S. Verhenne et al.   BLOOD

Safety of PEGylated recombinant human full-length coagulation factor VIII (BAX 855) in the overall context of PEG and PEG conjugates

(2015) R. Stidl et al.   HAEMOPHILIA

Does deficiency of von Willebrand factor protect against cardiovascular disease? Analysis of a national discharge register

(2015) C. D. Seaman et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

GpIb -VWF blockade restores vessel patency by dissolving platelet aggregates formed under very high shear rate in mice

(2014) A. Le Behot et al.   BLOOD

Von Willebrand factor and ADAMTS13 in arterial thrombosis: a systematic review and meta-analysis

(2014) Michelle A.H. Sonneveld et al.   BLOOD REVIEWS

Reduced prevalence of arterial thrombosis in von Willebrand disease

(2013) Y. V. Sanders et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

ARC15105 Is a Potent Antagonist of Von Willebrand Factor Mediated Platelet Activation and Adhesion

(2012) Jolanta M. Siller-Matula et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Effects of prasugrel on platelet inhibition during systemic endotoxaemia: a randomized controlled trial

(2012) Alexander O. Spiel et al.   CLINICAL SCIENCE

von Willebrand factor: the old, the new and the unknown

(2012) P. J. LENTING et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

The anti-von Willebrand factor aptamer ARC1779 increases von Willebrand factor levels and platelet counts in patients with type 2B von Willebrand disease

(2012) Petra Jilma-Stohlawetz et al.   THROMBOSIS AND HAEMOSTASIS

Initial experience from a double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura

(2011) Spero R. Cataland et al.   AMERICAN JOURNAL OF HEMATOLOGY

Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs

(2011) H. Ulrichts et al.   BLOOD

The von Willebrand Inhibitor ARC1779 Reduces Cerebral Embolization After Carotid Endarterectomy

(2011) Hugh S. Markus et al.   STROKE

von Willebrand Factor

(2011) Simon F. De Meyer et al.   STROKE

A dose ranging phase I/II trial of the von Willebrand factor inhibiting aptamer ARC1779 in patients with congenital thrombotic thrombo - cytopenic purpura

(2011) Petra Jilma-Stohlawetz et al.   THROMBOSIS AND HAEMOSTASIS

Binding of von Willebrand Factor to Collagen and Glycoprotein Ibα, But Not to Glycoprotein IIb/IIIa, Contributes to Ischemic Stroke in Mice—Brief Report

(2010) Simon F. De Meyer et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

A randomised pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with type 2b von Willebrand disease

(2010) Petra Paulinska et al.   THROMBOSIS AND HAEMOSTASIS

Inhibition of von Willebrand factor by ARC1779 in patients with acute thrombotic thrombocytopenic purpura

(2010) Bernd Jilma et al.   THROMBOSIS AND HAEMOSTASIS

von Willebrand factor assembly and secretion

(2009) J. E. SADLER   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Inhibition of von Willebrand factor-mediated platelet activation and thrombosis by the anti-von Willebrand factor A1-domain aptamer ARC1779

(2009) J. L. DIENER et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Doppler Embolic Signals in Cerebrovascular Disease and Prediction of Stroke Risk

(2009) Alice King et al.   STROKE

A Structural Explanation for the Antithrombotic Activity of ARC1172, a DNA Aptamer that Binds von Willebrand Factor Domain A1

(2009) Ren-Huai Huang et al.   STRUCTURE

Von Willebrand Factor in Cardiovascular Disease

(2008) Alexander O. Spiel et al.   CIRCULATION

Interspecies differences in coagulation profile

(2008) Jolanta M. Siller-Matula et al.   THROMBOSIS AND HAEMOSTASIS